Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 9/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837203 | 0.97 | S1PR3 (0.60) | S1PR3PTGDR2CSNK1DMAPK11MAPK14 | |
| SCHEMBL2834110 | 0.92 | S1PR3 (0.62) | S1PR3CSNK1DMAPK11MAPK14ESR1 | |
| SCHEMBL3997882 | 0.78 | S1PR3 (0.72) | S1PR3PTGDR2 | |
| SCHEMBL4002666 | 0.76 | CKS1B (0.54) | S1PR3 | |
| SCHEMBL291259 | 0.76 | S1PR3 (1.00) | S1PR3 | |
| SCHEMBL803571 | 0.76 | S1PR3 (1.00) | S1PR3PTGDR2 | |
| SCHEMBL805645 | 0.75 | S1PR3 (0.94) | S1PR3 | |
| SCHEMBL3999452 | 0.74 | CNR1 (0.53) | S1PR3 | |
| SCHEMBL805685 | 0.74 | S1PR3 (1.00) | S1PR3PTGDR2 | |
| SCHEMBL5214542 | 0.70 | NR1I2 (0.58) | S1PR3CSNK1DMAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262497-A2 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | Allergan, Inc. (US) | 2010-12-22 | — | — | EP | claimed |
| WO-2009117335-A2 | S1P3 RECEPTOR INHIBITORS FOR TREATING INFLAMMATION | ALLERGAN, INC. (US) | 2009-09-24 | — | — | WO | claimed |
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | ALLERGAN, INC. (US) | 2014-01-09 | — | — | US | disclosed |
| US-8563594-B2 | S1P3 receptor inhibitors for treating pain | ALLERGAN, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | ALLERGAN, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2427189-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING CONDITIONS OF THE EYE | Allergan, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129553-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING CONDITIONS OF THE EYE | ALLERGAN, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100249069-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | DONELLO JOHN E | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011771-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | S1PR3, LPAR3, S1PR2 | S1PR3 1/4885PTGDR2 198/4885CSNK1D 1651/4885 |
| US-20120071448-A1 | S1P3 Receptor Inhibitors for Treating Conditions of the Eye | S1PR3, S1PR1, S1PR2 | S1PR3 1/4885PTGDR2 186/4885CSNK1D 3211/4885 |
| US-20100249069-A1 | S1P3 RECEPTOR INHIBITORS FOR TREATING PAIN | S1PR3, LPAR3, S1PR2 | S1PR3 1/4885PTGDR2 198/4885CSNK1D 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.